Top Markets
#1 Black Phoenix Black Phoenix +734.77%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.07%
#3 TENDIES TENDIES +19.72%
#4 Biconomy Biconomy +19.10%
#5 THORChain THORChain +18.60%
#6 MetaDAO MetaDAO +18.10%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +18.08%
#8 THORChain Yield THORChain Yield +13.81%
#9 Derive Derive +10.27%
#10 Bless Bless +9.92%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Mirati Therapeutics, Inc. Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc.

MRTX
Rank in Stocks #5110
Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the... Mirati Therapeutics, Inc. is a U.S.-based biotechnology firm operating at the clinical stage, committed to identifying and developing treatments that target the genetic and immunological factors driving cancer progression. Its pipeline features MRTX849, a KRAS G12C inhibitor currently undergoing Phase 1/2 clinical trials for a range of malignancies, including non-small cell lung, colorectal, and pancreatic cancers. Additionally, the company is advancing Sitravatinib, an investigational broad-spectrum kinase inhibitor, which has reached Phase 3 clinical trials specifically for non-small cell lung cancer. Mirati also has a KRAS G12D inhibitor program in its preclinical development phase. The company has forged a collaboration and licensing agreement with BeiGene, Ltd. for the development, manufacturing, and commercialization of sitravatinib. Established in 1995, Mirati Therapeutics, Inc. maintains its headquarters in San Diego, California.
Share Price
$58.70
Last synced: 2024-01-23
Market Cap
$2.98B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Mirati Therapeutics, Inc. (MRTX)

Category

Healthcare
Revenue for Mirati Therapeutics, Inc. (MRTX)
Revenue in Aug 2026 TTM: 0
According to Mirati Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Mirati Therapeutics, Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH